Get the Stockscreener App
3.25
1.22%
-0.04
After Hours:
3.20
-0.05
-1.54%
Relay Therapeutics Inc stock is traded at $3.25, with a volume of 2.47M.
It is down -1.22% in the last 24 hours and up +30.52% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$3.29
Open:
$3.31
24h Volume:
2.47M
Relative Volume:
1.11
Market Cap:
$545.56M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.1607
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
+1.56%
1M Performance:
+30.52%
6M Performance:
-44.35%
1Y Performance:
-54.10%
1-Day Range:
$3.17
$3.365
1-Week Range:
$2.96
$3.47
52-Week Range:
$1.775
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.25 | 545.56M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
There Is A Lot Of Upside Potential For Relay Therapeutics Inc(NASDAQ: RLAY) - Stocksregister
why Relay Therapeutics Inc [RLAY] is a Good Choice for Investors After New Price Target of $17.40 - dbtnews.com
LPL Financial LLC Sells 6,564 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics president sells $95,381 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics chief legal officer sells $44,040 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics CFO sells shares worth $44,246 By Investing.com - Investing.com South Africa
Relay Therapeutics Inc Stock: Executives Sell Shares Amid Mixed Signals - sharewise
Relay Therapeutics CFO sells shares worth $44,246 - Investing.com Australia
Relay Therapeutics chief legal officer sells $44,040 in stock - Investing.com
Relay Therapeutics president sells $95,381 in stock - Investing.com
Relay Therapeutics executive sells $36,540 in stock - Investing.com
Relay Therapeutics Executives Sell Shares to Cover Tax Obligations and Under Trading Plan - TradingView
Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - Sete News
Trading Day Review: Relay Therapeutics Inc (RLAY) Loses Momentum, Closing at 3.10 - DWinneX
Relay Therapeutics Inc: Weathering Stock Market Storms with 528.51M Market Cap - investchronicle.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Legal & General Group Plc - Defense World
RLAY (Relay Therapeutics Inc) may reap gains as insiders became active recently - knoxdaily.com
Relay Therapeutics Inc (RLAY) shows promising results - uspostnews.com
Relay Therapeutics to Announce First Quarter 2025 Financial Resu - GuruFocus
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025 - The Manila Times
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Relay Therapeutics Q1 2025 Earnings: Precision Medicine Pioneer Reports Financial Results May 5 - Stock Titan
Russell Investments Group Ltd. Has $329,000 Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics (RLAY) Expected to Announce Quarterly Earnings on Thursday - Defense World
Ready to Jump After Recent Trade: Relay Therapeutics Inc (RLAY) - Sete News
Keeping an Eye on Relay Therapeutics Inc (RLAY) After Insider Trading Activity - knoxdaily.com
Upward Trajectory: Relay Therapeutics Inc (RLAY) Posts a Gaine, Closing at 2.93 - DWinneX
Relay Therapeutics Inc (RLAY)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Small Cap Stock Relay Therapeutics Inc (RLAY) Is A Buy – Analysts - Marketing Sentinel
Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Lifted by Geode Capital Management LLC - Defense World
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights - ADVFN
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts - Yahoo Finance
Franklin Resources Inc. Sells 1,338,037 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Wells Fargo & Company Begins Coverage on Relay Therapeutics (NASDAQ:RLAY) - Defense World
Wells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight Recommendation - Nasdaq
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Wells Fargo Initiates Relay Therapeutics at Equalweight With $4 Price Target - marketscreener.com
Relay Therapeutics (RLAY) Assigned Equal Weight by Wells Fargo | - GuruFocus
Relay Therapeutics (RLAY) Assigned Equal Weight by Wells Fargo | RLAY Stock News - GuruFocus
Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Relay Therapeutics: Trying To Find That Right Price - Seeking Alpha
Corebridge Financial Inc. Acquires 7,314 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Vanguard Group Inc. Acquires 566,595 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics Inc (NASDAQ: RLAY): Blank Check On Growth? - stocksregister.com
KLP Kapitalforvaltning AS Purchases New Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
American Century Companies Inc. Buys 51,499 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple - Insider Monkey
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):